CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 87.41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Scan to Download iOS&Android APP

Trade Recursion Pharmaceuticals, Inc. - RXRX CFD

9.07
0.22%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0308%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.0308 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Go to platform
-0.0137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 9.08
Open* 9.06
1-Year Change* 1.91%
Day's Range* 8.84 - 8.84
52 wk Range 4.92-21.1894
Average Volume (10 days) 1.58084
Average Volume (3 months) 25.0471
Market Cap 1759.08
P/E Ratio N/A
Shares Outstanding 197417000
Revenue 28.7
EPS -1.43945
Dividend (Yield %) N/A
Beta N/A
Next Earnings Date Mar 21, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 5, 2022 9.08 -0.16 -1.73% 9.24 9.33 8.94
Dec 2, 2022 9.27 0.28 3.11% 8.99 9.35 8.92
Dec 1, 2022 9.27 0.67 7.79% 8.60 9.47 8.60
Nov 30, 2022 9.36 0.45 5.05% 8.91 9.38 8.35
Nov 29, 2022 8.81 0.67 8.23% 8.14 8.88 8.14
Nov 28, 2022 8.32 -0.76 -8.37% 9.08 9.27 8.22
Nov 25, 2022 9.14 0.05 0.55% 9.09 9.48 9.08
Nov 23, 2022 9.21 0.16 1.77% 9.05 9.69 9.04
Nov 22, 2022 9.24 0.26 2.90% 8.98 9.39 8.49
Nov 21, 2022 9.05 -0.37 -3.93% 9.42 9.49 8.77
Nov 18, 2022 9.78 -0.87 -8.17% 10.65 11.14 9.16
Nov 17, 2022 10.88 -0.45 -3.97% 11.33 11.36 10.72
Nov 16, 2022 11.21 -0.38 -3.28% 11.59 11.77 10.58
Nov 15, 2022 11.82 -0.72 -5.74% 12.54 12.58 11.29
Nov 14, 2022 12.68 0.29 2.34% 12.39 13.23 12.33
Nov 11, 2022 12.45 1.52 13.91% 10.93 12.53 10.93
Nov 10, 2022 11.05 0.71 6.87% 10.34 11.22 10.34
Nov 9, 2022 10.22 0.64 6.68% 9.58 10.45 9.53
Nov 8, 2022 9.55 0.17 1.81% 9.38 9.79 9.18
Nov 7, 2022 9.36 -0.28 -2.90% 9.64 9.75 9.22

Recursion Pharmaceuticals, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2019 2020 2021
Total revenue 2.319 3.962 10.178
Revenue 2.319 3.962 10.178
Total Operating Expense 65.315 89.46 193.78
Selling/General/Admin. Expenses, Total 19.898 27.035 66.671
Research & Development 44.862 61.542 125.978
Unusual Expense (Income) 0.555 0.883 0.827
Operating Income -62.996 -85.498 -183.602
Interest Income (Expense), Net Non-Operating 1.106 -1.024 -2.879
Other, Net 0.011 -0.484 0.002
Net Income Before Taxes -61.879 -87.006 -186.479
Net Income After Taxes -61.879 -87.006 -186.479
Net Income Before Extra. Items -61.879 -87.006 -186.479
Net Income -61.879 -87.006 -186.479
Income Available to Common Excl. Extra. Items -61.879 -87.006 -186.479
Income Available to Common Incl. Extra. Items -61.879 -87.006 -186.479
Diluted Net Income -61.879 -87.006 -186.479
Diluted Weighted Average Shares 162.155 162.155 125.348
Diluted EPS Excluding Extraordinary Items -0.3816 -0.53656 -1.48769
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.37818 -0.53111 -1.48109
Depreciation / Amortization 0.304
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 2.562 2.549 2.534 2.533 5.333
Revenue 2.562 2.549 2.534 2.533 5.333
Total Operating Expense 33.046 43.478 49.763 67.493 61.314
Selling/General/Admin. Expenses, Total 8.937 13.854 15.69 21.419 21.074
Research & Development 24.033 29.548 33.17 45.998 32.365
Depreciation / Amortization 0.076 0.076 0.076 0.076 0.076
Operating Income -30.484 -40.929 -47.229 -64.96 -55.981
Interest Income (Expense), Net Non-Operating -0.233 -2.472 -0.17 -0.002 0.073
Net Income Before Taxes -30.717 -43.401 -47.428 -64.933 -55.979
Net Income After Taxes -30.717 -43.401 -47.428 -64.933 -55.979
Net Income Before Extra. Items -30.717 -43.401 -47.428 -64.933 -55.979
Net Income -30.717 -43.401 -47.428 -64.933 -55.979
Income Available to Common Excl. Extra. Items -30.717 -43.401 -47.428 -64.933 -55.979
Income Available to Common Incl. Extra. Items -30.717 -43.401 -47.428 -64.933 -55.979
Diluted Net Income -30.717 -43.401 -47.428 -64.933 -55.979
Diluted Weighted Average Shares 168.321 138.361 168.534 169.853 170.69
Diluted EPS Excluding Extraordinary Items -0.18249 -0.31368 -0.28142 -0.38229 -0.32796
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.18249 -0.31368 -0.27651 -0.38229 -0.32796
Unusual Expense (Income) 0.827 0
Other, Net -0.029 0.029 -0.071
Cost of Revenue, Total 7.799
Gross Profit -2.466
  • Annual
  • Quarterly
2019 2020 2021
Total Current Assets 76.398 266.437 534.718
Cash and Short Term Investments 69.883 262.126 516.562
Cash & Equivalents 69.883 262.126 285.116
Total Receivables, Net 0.151 0.156 9.09
Accounts Receivable - Trade, Net 0.151 0.156 0.034
Other Current Assets, Total 6.364 4.155 9.066
Total Assets 101.431 298.585 610.345
Property/Plant/Equipment, Total - Net 24.37 25.967 64.725
Property/Plant/Equipment, Total - Gross 30.085 35.929 83.462
Accumulated Depreciation, Total -5.715 -9.962 -18.737
Intangibles, Net 0 1.689 1.385
Other Long Term Assets, Total 0.663 3.691 8.716
Total Current Liabilities 6.684 23.099 46.658
Accounts Payable 1.261 1.074 2.819
Accrued Expenses 5.346 10.952 33.749
Notes Payable/Short Term Debt 0 0 0
Current Port. of LT Debt/Capital Leases 0.077 1.073 0.09
Other Current Liabilities, Total 0 10 10
Total Liabilities 24.587 56.562 67.407
Total Long Term Debt 12.418 11.414 0.633
Long Term Debt 12.418 11.414 0.633
Other Liabilities, Total 5.485 22.049 20.116
Total Equity 76.844 242.023 542.938
Preferred Stock - Non Redeemable, Net 201.109 448.312 0
Common Stock 0 0 0.002
Additional Paid-In Capital 2.33 7.312 943.142
Retained Earnings (Accumulated Deficit) -126.595 -213.601 -400.08
Total Liabilities & Shareholders’ Equity 101.431 298.585 610.345
Total Common Shares Outstanding 162.155 162.155 170.272
Short Term Investments 0 231.446
Goodwill, Net 0.801 0.801
Other Equity, Total 0 -0.126
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 221.822 647.635 600.87 534.718 619.455
Cash and Short Term Investments 214.088 632.738 578.91 516.562 591.105
Cash & Equivalents 214.088 632.738 394.721 285.116 507.891
Total Receivables, Net 0.071 0.049 2.282 9.09 11.397
Accounts Receivable - Trade, Net 0.071 0.049 0.034 0.034 0.034
Other Current Assets, Total 7.663 14.848 19.678 9.066 16.953
Total Assets 271.943 698.59 658.606 610.345 734.319
Property/Plant/Equipment, Total - Net 44.642 48.549 55.439 64.725 104.005
Property/Plant/Equipment, Total - Gross 56.036 62.306 71.662 83.462 125.433
Accumulated Depreciation, Total -11.394 -13.757 -16.223 -18.737 -21.428
Intangibles, Net 2.414 2.338 2.262 1.385 1.309
Other Long Term Assets, Total 3.065 0.068 0.035 8.716 8.749
Total Current Liabilities 26.854 29.54 42.943 46.658 85.705
Accounts Payable 3.125 3.196 6.326 2.819 4.162
Accrued Expenses 11.584 13.209 26.529 33.749 27.204
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 2.145 3.135 0.088 0.09 0.092
Other Current Liabilities, Total 10 10 10 10 54.247
Total Liabilities 56.662 55.876 59.574 67.407 240.753
Total Long Term Debt 10.339 9.423 0.656 0.633 0.61
Long Term Debt 10.339 9.423 0.656 0.633 0.61
Other Liabilities, Total 19.469 16.913 15.975 20.116 154.438
Total Equity 215.281 642.714 599.032 542.938 493.566
Redeemable Preferred Stock 450.85
Preferred Stock - Non Redeemable, Net -2.538 0 0 0
Common Stock 0 0.002 0.002 0.002 0.002
Additional Paid-In Capital 11.287 930.431 934.175 943.142 949.932
Retained Earnings (Accumulated Deficit) -244.318 -287.719 -335.147 -400.08 -456.059
Total Liabilities & Shareholders’ Equity 271.943 698.59 658.606 610.345 734.319
Total Common Shares Outstanding 168.321 168.426 168.635 170.272 171.078
Short Term Investments 184.189 231.446 83.214
Other Equity, Total 0.002 -0.126 -0.309
Goodwill, Net 0.801 0.801
  • Annual
  • Quarterly
2019 2020 2021
Net income/Starting Line -61.879 -87.006 -186.479
Cash From Operating Activities -57.042 -45.399 -158.614
Cash From Operating Activities 3.543 4.442 8.405
Non-Cash Items 0.886 6.331 19.766
Cash Interest Paid 0.485 0.989 0.68
Changes in Working Capital 0.408 30.834 -0.306
Cash From Investing Activities -3.91 -8.74 -271.744
Capital Expenditures -3.91 -5.831 -39.798
Other Investing Cash Flow Items, Total 0 -2.909 -231.946
Cash From Financing Activities 120.41 246.135 458.54
Financing Cash Flow Items -0.275 0 0
Issuance (Retirement) of Stock, Net 119.98 239.812 471.338
Issuance (Retirement) of Debt, Net 0.705 6.323 -12.798
Net Change in Cash 59.458 191.996 28.182
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -30.717 -74.118 -121.546 -186.479 -55.979
Cash From Operating Activities -30.755 -64.408 -97.456 -158.614 77.388
Cash From Operating Activities 1.402 3.733 6.169 8.405 2.767
Non-Cash Items 1.922 9.614 14.268 19.766 7.776
Cash Interest Paid 0.254 0.54 0.665 0.68 0.014
Changes in Working Capital -3.362 -3.637 3.653 -0.306 122.824
Cash From Investing Activities -19.416 -25.628 -219.501 -271.744 143.304
Capital Expenditures -19.416 -25.628 -35.334 -39.798 -4.342
Cash From Financing Activities 2.134 465.839 454.744 458.54 2.084
Issuance (Retirement) of Stock, Net 2.154 465.879 462.901 471.338 2.106
Issuance (Retirement) of Debt, Net -0.02 -0.04 -12.777 -12.798 -0.022
Net Change in Cash -48.037 375.803 137.787 28.182 222.776
Other Investing Cash Flow Items, Total 0 -184.167 -231.946 147.646
Financing Cash Flow Items 4.62
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Baillie Gifford & Co. Investment Advisor 11.8852 21594693 -10992 2022-09-30 LOW
Mubadala Investment Company PJSC Sovereign Wealth Fund 10.8664 19743695 2551020 2022-10-27 LOW
Lux Capital Management, LLC Venture Capital 7.1667 13021519 0 2022-03-31 LOW
DCVC Management Co, LLC Venture Capital 5.4444 9892261 0 2022-09-30 LOW
MIC Capital Management UK LLP Investment Advisor 4.6516 8451758 0 2022-09-30 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.6084 8373178 1393519 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.5728 8308494 1476128 2022-09-30 LOW
Borgeson (Blake Charles Ph.D.) Individual Investor 4.2082 7646042 -26655 2022-11-29 LOW
Laurion Capital Management LP Hedge Fund 2.5247 4587274 0 2022-09-30 HIGH
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.5074 4555759 2430027 2022-09-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 2.3397 4251164 1415312 2022-09-30 LOW
Obvious Ventures Venture Capital 2.1933 3985087 -1992544 2022-09-30 LOW
Li (Dean Y) Individual Investor 2.0928 3802529 1092 2022-10-03 LOW
ARK Investment Management LLC Investment Advisor 1.8492 3359811 627724 2022-09-30 LOW
AllianceBernstein L.P. Investment Advisor/Hedge Fund 1.7818 3237344 -363616 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.2835 2332083 826087 2022-09-30 LOW
Platinum Asset Management Investment Advisor/Hedge Fund 1.2394 2251971 -283651 2022-09-30 LOW
Menlo Ventures Venture Capital 1.0853 1971908 0 2022-09-30 MED
Credit Suisse Asset Management Investment Advisor/Hedge Fund 0.861 1564459 -340 2022-09-30 LOW
Harvard Management Company, Inc. Endowment Fund 0.8307 1509254 0 2022-09-30 MED

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
475000+

Traders

71000+

Active clients monthly

$51000000+

Monthly investing volume

$30000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

Recursion Pharmaceuticals, Inc. Company profile

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company uses Recursion Operating System (Recursion OS), a multi-layer system for generating, analyzing and deriving insights from biological and chemical datasets. It consists of three parts: Infrastructure Layer, The Recursion Data Universe and The Recursion Map. Its programs include REC-4881, REC-3599, REC-2282, REC-994, lead molecules for the treatment of C. difficile Colitis, lead molecules for the treatment of Neuroinflammation, lead molecules for the treatment of Batten Disease and lead molecules for the treatment of CMT2A.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Recursion Pharmaceuticals Inc revenues totaled $7.6M. Net loss totaled to $121.5M.

Industry: Bio Therapeutic Drugs

41S Rio Grande Street
SALT LAKE CITY
UTAH 84101
US

Income Statement

People also watch

Natural Gas

5.40 Price
-4.090% 1D Chg, %
Long position overnight fee 0.0407%
Short position overnight fee -0.0655%
Overnight fee time 22:00 (UTC)
Spread 0.005

BTC/USD

17,007.10 Price
-0.030% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 60.00

Oil - Crude

74.42 Price
-3.990% 1D Chg, %
Long position overnight fee -0.0095%
Short position overnight fee -0.0056%
Overnight fee time 22:00 (UTC)
Spread 0.03

XRP/USD

0.39 Price
+0.170% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00367

Still looking for a broker you can trust?

Join the 475.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading